Single nucleotide polymorphisms in treatment of polycystic ovary syndrome: a systematic review

Abstract

As 15–20% of reproductive aged females are suffering from polycystic ovary syndrome (PCOS), a large number of pharmacological preparations are frequently available in the market for the treatment of PCOS; however, they seem to be ineffective and cause undesirable side effects. This has emphasized the need to optimize dosage regimens for individualized treatment. The objective of this systematic review is to review single nucleotide polymorphisms (SNPs) associated with drugs used for the treatment of PCOS to understand pharmacogenetics variability of patients to drug response there by helping clinicians in designing tailored treatments and possibly reducing adverse drug reactions. A comprehensive electronic literature search was conducted to highlight some clinically relevant SNPs that act to influence PCOS and associated co-morbidities. A total of 16 studies were included in this review. These genetic variations can be used as a potential target for pharmacotherapy and pharmacogenetic clinical trials for better diagnosis, management, and treatment planning.

Keywords:

• Single nucleotide polymorphism
• polycystic ovary syndrome
• pharmacogenetics
• treatment
• co-morbidities
• pharmacotherapy

Acknowledgement

The authors are thankful to Vinay Narwal, for critically revising the manuscript.

Disclosure statement

No potential conflict of interest was reported by the authors.